查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1954808

支原体检测市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2026-2034 年）

Mycoplasma Testing Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 180 Pages | 商品交期: 请询问到货日

价格

支原体侦测市场成长驱动因素

2025 年全球支原体检测市值为 9.723 亿美元。预计到 2026 年，该市场将成长至 10.211 亿美元，并在 2034 年进一步达到 15.517 亿美元，在预测期（2026-2034 年）内复合年增长率 (CAGR) 为 5.40%。

北美地区在 2025 年占市场主导地位，市占率为 49.20%，这得益于其强大的研究基础设施、不断加强的监管措施以及高额的研发投入。

支原体是最小的独立生活微生物，也是细胞培养中最常见的污染源之一。 生物製药生产。 由于缺乏坚硬的细胞壁，它们对许多抗生素具有抗药性，并且可以通过标准过滤系统。有鑑于此特性，实验室、疫苗生产和生物製药生产中必须定期进行支原体检测，以防止污染和经济损失。

新冠疫情的影响

由于疫苗和药物研发中细胞培养物的储存和检测增加，新冠疫情对市场产生了积极影响。疫苗研发的激增促使2020年对检测试剂盒和试剂的需求显着增加。虽然需求在2021年趋于正常，但预计针对慢性病和传染病的持续研发活动将支撑市场稳定成长至2034年。

市场趋势

策略联盟增多

诊断公司之间联盟的增加正在推动对先进检测技术的需求成长。 市场参与者正专注于併购和合作，以整合专业知识并强化其产品组合。旨在缩短检测时间和提高灵敏度的技术创新正受到製药和生物技术公司的关注。

基于PCR的检测技术进步

基于PCR的检测方法因其高灵敏度、特异性和快速出结果而日益普及。核酸扩增技术（NAT）的采用和监管指南的更新进一步加速了先进检测解决方案的应用。

市场成长驱动因素

生物製药和生技公司研发投入的增加是主要的成长驱动因素。随着疫苗开发、细胞疗法和生物製品投资的增加，对严格的污染控制措施的需求也随之增加，推动了对检测试剂盒的需求。

全球医疗保健支出的成长以及人们对细胞培养污染的日益关注也促进了市场成长。 更新的监管标准和品质控制指南正在推动实验室和研究机构进行常规检测。

限制因子

先进检测试剂盒和设备的高昂成本可能会限制新兴市场的采用。基于PCR的试剂盒和检测系统需要专用设备和训练有素的专业人员，从而增加了整体营运成本。此外，全球熟练实验室人员的短缺可能会阻碍某些地区的市场扩张。

市场区隔分析

依产品划分

此市场细分分为试剂和试剂盒以及仪器。

  • 由于常规检测中的频繁使用以及新产品的增加，试剂和试剂盒细分市场预计将在2026年占57.85%的市场占有率。
  • 由于新兴市场渗透率的提高和技术进步，仪器细分市场预计将保持稳定成长。

依检测方法

市场分为基于PCR、基于培养和其他方法。

  • 预计到2026年，基于PCR的检测方法将占56.92%的市场占有率，主要得益于其高灵敏度、高效率和短处理时间。
  • 由于处理时间长、灵敏度低，基于培养的检测方法预计成长率较低，但其低成本正在推动其在发展中地区的普及。

依应用

应用包括细胞培养、疫苗检测和病毒检测。

  • 预计到2026年，细胞培养领域将占37.36%的市场占有率，主要得益于日益增长的污染担忧和不断增加的研究活动。
  • 预计2034年，病毒检测领域将达到最高的复合年增长率，主要得益于疫情监测的加强。
  • 疫苗测试持续受益于免疫接种计画的扩展和研发投入的增加。

依最终使用者划分

市场细分包括生物製药和生物技术公司、细胞库、合约研究组织/合约生产组织 (CRO/CMO) 以及其他公司。

  • 生物製药和生技公司预计将以 32.99% 的市占率领先，这主要得益于其研发管线的扩展。
  • 细胞库预计将实现最高的复合年增长率 (CAGR)，这主要得益于对干细胞和其他生物样本储存需求的不断增长。

区域洞察

北美

北美仍然是领先的地区。 预计到2026年，该地区市场规模将达到5.032亿美元，其中美国市场预计为4.596亿美元。政府的大力投入和疫苗研发措施将持续推动市场需求。

欧洲

预计欧洲市场将实现温和成长。受研发投入增加的推动，英国市场预计到2026年将达到4,930万美元，德国市场预计到2026年将达到3,770万美元。

亚太地区

预计到2034年，亚太地区将达到最高的复合年增长率。受生物製药领域合作拓展与成长的推动，预计到2026年，日本市场将达到5,240万美元，中国市场将达到4,230万美元，印度市场将达到3,780万美元。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 2025年主要地区/国家研发支出概览
  • 支原体侦测技术进展
  • 产业主要发展动态－併购与合作
  • 新产品发布
  • 新冠疫情对市场的影响

第五章：全球支原体检测市场分析、洞察与预测 (2021-2034)

  • 市场分析、洞察与预测 - 依检测方法划分
    • 基于PCR的方法
    • 基于培养的方法
    • 其他方法
  • 市场分析、洞察与预测 - 依产品划分
    • 设备
    • 试剂和试剂盒
  • 市场分析、洞察与预测 - 依应用划分
    • 细胞培养
    • 疫苗检测
    • 病毒检测
    • 其他
  • 市场分析、洞察与预测 - 依最终用户划分
    • 生物製药和生物技术公司
    • 细胞库
    • 合约研究与生产组织
    • 其他
  • 市场分析、洞察与预测 - 依区域
    • 北美洲
    • 欧洲
    • 亚太地区
    • 世界其他地区

第六章 北美洲支原体检测市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲支原体检测市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 其他欧洲国家

第八章 亚太地区支原体检测市场分析、洞察与预测2021-2034

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 其他亚太地区

第九章：全球其他地区支原体检测市场分析、洞察与预测（2021-2034）

第10章 竞争分析

  • 全球市场占有率分析(2025年)
  • 企业简介
    • Merck KGaA
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd.
    • Sartorius AG
    • Asahi Kasei Corporation
    • Biomeriux SA
    • Charles River Laboratories
    • ATCC
    • Other Prominent Players
Product Code: FBI108687

Growth Factors of mycoplasma testing Market

The global mycoplasma testing market was valued at USD 972.3 million in 2025. The market is projected to grow to USD 1,021.10 million in 2026 and further reach USD 1,551.70 million by 2034, registering a CAGR of 5.40% during the forecast period (2026-2034).

North America dominated the market with a 49.20% share in 2025, supported by strong research infrastructure, rising regulatory initiatives, and high R&D expenditure.

Mycoplasma are the smallest free-living organisms and are among the most common contaminants in cell cultures and biopharmaceutical production. Due to their lack of a rigid cell wall, they are resistant to many antibiotics and can pass through standard filtration systems. This makes routine mycoplasma testing essential in research laboratories, vaccine production, and biologics manufacturing to prevent contamination and financial losses.

COVID-19 Impact

The COVID-19 pandemic positively impacted the market due to increased storage and testing of cell cultures for vaccine and drug development. The surge in vaccine R&D significantly increased demand for testing kits and reagents in 2020. Although demand normalized in 2021, continued R&D activities for chronic diseases and infectious conditions are expected to support steady market growth through 2034.

Market Trends

Increasing Strategic Partnerships

Rising demand for advanced testing technologies has led to increased collaborations among diagnostic companies. Market players are focusing on mergers, acquisitions, and partnerships to combine expertise and enhance product portfolios. Technological advancements aimed at reducing turnaround time and improving sensitivity are gaining traction among pharmaceutical and biotechnology companies.

Technological Advancements in PCR-Based Testing

PCR-based testing methods are becoming more popular due to their high sensitivity, specificity, and faster results. Adoption of nucleic acid amplification techniques (NAT) and regulatory guideline updates are further accelerating the use of advanced testing solutions.

Market Growth Drivers

The increasing R&D expenditure among biopharmaceutical and biotechnology companies is a major driver. Growing investments in vaccine development, cell therapies, and biologics require strict contamination control measures, boosting demand for testing kits.

Rising healthcare expenditure globally and growing awareness regarding cell culture contamination are further contributing to market growth. Updated regulatory standards and quality control guidelines are encouraging routine testing in laboratories and research facilities.

Restraining Factors

High costs associated with advanced testing kits and instruments may limit adoption in emerging markets. PCR-based kits and detection systems require specialized equipment and trained professionals, increasing overall operational costs. Additionally, the shortage of skilled laboratory personnel globally may hinder market expansion in certain regions.

Segmentation Analysis

By Product

The market is segmented into reagents & kits and instruments.

  • The reagents & kits segment dominated the market with a 57.85% share in 2026, driven by their frequent usage in routine laboratory testing and rising product launches.
  • The instruments segment is expected to grow steadily due to increasing penetration in emerging markets and technological advancements.

By Testing Method

The market is categorized into PCR-based, culture-based, and others.

  • The PCR-based segment is projected to lead with a 56.92% share in 2026, owing to high sensitivity, efficiency, and shorter turnaround time.
  • The culture-based segment is expected to grow at a slower rate due to longer processing time and lower sensitivity, although its lower cost supports adoption in developing regions.

By Application

Applications include cell culture, vaccine testing, virus testing, and others.

  • The cell culture segment will account for 37.36% share in 2026, supported by rising contamination concerns and increasing research activities.
  • The virus testing segment is anticipated to register the highest CAGR through 2034 due to increasing outbreak monitoring.
  • Vaccine testing continues to benefit from growing immunization programs and R&D investments.

By End-user

The market is segmented into biopharmaceutical & biotechnology companies, cell banks, CROs & CMOs, and others.

  • The biopharmaceutical & biotechnology companies segment is projected to lead with a 32.99% share, driven by expanding R&D pipelines.
  • The cell banks segment is expected to register the highest CAGR due to growing storage of stem cells and other biological samples.

Regional Insights

North America

North America remains the dominant region. The market in the region reached USD 503.2 million in 2026, with the U.S. market estimated at USD 459.6 million in 2026. Strong government funding and vaccine development initiatives continue to drive demand.

Europe

Europe is expected to grow at a moderate rate. The UK market is projected to reach USD 49.3 million by 2026, while Germany is estimated at USD 37.7 million in 2026, supported by rising R&D investments.

Asia Pacific

Asia Pacific is projected to register the highest CAGR through 2034. Japan is estimated to reach USD 52.4 million by 2026, China USD 42.3 million, and India USD 37.8 million, driven by increasing collaborations and expanding biopharmaceutical sectors.

Competitive Landscape

The market is fragmented, with key players including Merck KGaA, Thermo Fisher Scientific Inc., Lonza, F. Hoffmann-La Roche Ltd., Sartorius AG, bioMerieux SA, and Asahi Kasei Corporation.

Companies are focusing on technological innovation, product launches, partnerships, and facility expansions to strengthen their global presence. Strategic initiatives and R&D investments are expected to intensify competition through 2034.

Conclusion

The global mycoplasma testing market is projected to grow from USD 972.3 million in 2025 to USD 1,551.70 million by 2034, driven by rising R&D activities, increasing contamination concerns, and technological advancements in PCR-based testing. While high costs and skilled workforce shortages may restrain growth in emerging markets, expanding vaccine production, biologics development, and regulatory compliance requirements will sustain long-term market expansion. North America will continue to dominate, while Asia Pacific is expected to witness the fastest growth through 2034.

Segmentation By Testing Method

  • PCR-based
  • Culture-based
  • Others

By Product

  • Instruments
  • Reagents & Kits

By Application

  • Cell Culture
  • Vaccine Testing
  • Virus Testing
  • Others

By End-user

  • Biopharmaceutical & Biotechnology Companies
  • Cell banks
  • Contract Research Organizations & Contract Manufacturing Organizations
  • Others

By Region

  • North America (By Testing Method, Product, Application, End-user, and By Country)
    • U.S. (By Testing Method)
    • Canada (By Testing Method)
  • Europe (By Testing Method, Product, Application, End-user, and Country/Sub-region)
    • U.K. (By Testing Method)
    • Germany (By Testing Method)
    • France (By Testing Method)
    • Italy (By Testing Method)
    • Spain (By Testing Method)
    • Rest of Europe (By Testing Method)
  • Asia Pacific (By Testing Method, Product, Application, End-user, and Country/Sub-region)
    • China (By Testing Method)
    • Japan (By Testing Method)
    • India (By Testing Method)
    • Australia (By Testing Method)
    • Southeast Asia (By Testing Method)
    • Rest of Asia Pacific (By Testing Method)
  • Rest of the World (By Testing Method, Product, Application, and End-user)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of R&D Expenditure, Key Regions/Key Countries, 2025
  • 4.2. Technological Advancements in Mycoplasma Testing
  • 4.3. Key Industry Developments - Mergers, Acquisitions & Partnership
  • 4.4. New Product Launches
  • 4.5. Impact of COVID-19 on the Market

5. Global Mycoplasma Testing Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Testing Method
    • 5.1.1. PCR-based
    • 5.1.2. Culture-based
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Product
    • 5.2.1. Instruments
    • 5.2.2. Reagents & Kits
  • 5.3. Market Analysis, Insights and Forecast - By Application
    • 5.3.1. Cell Culture
    • 5.3.2. Vaccine Testing
    • 5.3.3. Virus Testing
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Biopharmaceutical & Biotechnology Companies
    • 5.4.2. Cell banks
    • 5.4.3. Contract Research Organizations & Contract Manufacturing Organizations
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Rest of the World

6. North America Mycoplasma Testing Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Testing Method
    • 6.1.1. PCR-based
    • 6.1.2. Culture-based
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Product
    • 6.2.1. Instruments
    • 6.2.2. Reagents & Kits
  • 6.3. Market Analysis, Insights and Forecast - By Application
    • 6.3.1. Cell Culture
    • 6.3.2. Vaccine Testing
    • 6.3.3. Virus Testing
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Biopharmaceutical & Biotechnology Companies
    • 6.4.2. Cell banks
    • 6.4.3. Contract Research Organizations & Contract Manufacturing Organizations
    • 6.4.4. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 6.5.1. U.S.
      • 6.5.1.1. By Testing Method
    • 6.5.2. Canada
      • 6.5.2.1. By Testing Method

7. Europe Mycoplasma Testing Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Testing Method
    • 7.1.1. PCR-based
    • 7.1.2. Culture-based
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Product
    • 7.2.1. Instruments
    • 7.2.2. Reagents & Kits
  • 7.3. Market Analysis, Insights and Forecast - By Application
    • 7.3.1. Cell Culture
    • 7.3.2. Vaccine Testing
    • 7.3.3. Virus Testing
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Biopharmaceutical & Biotechnology Companies
    • 7.4.2. Cell banks
    • 7.4.3. Contract Research Organizations & Contract Manufacturing Organizations
    • 7.4.4. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.5.1. U.K
      • 7.5.1.1. By Testing Method
    • 7.5.2. Germany
      • 7.5.2.1. By Testing Method
    • 7.5.3. France
      • 7.5.3.1. By Testing Method
    • 7.5.4. Spain
      • 7.5.4.1. By Testing Method
    • 7.5.5. Italy
      • 7.5.5.1. By Testing Method
    • 7.5.6. Rest of Europe
      • 7.5.6.1. By Testing Method

8. Asia Pacific Mycoplasma Testing Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Testing Method
    • 8.1.1. PCR-based
    • 8.1.2. Culture-based
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Product
    • 8.2.1. Instruments
    • 8.2.2. Reagents & Kits
  • 8.3. Market Analysis, Insights and Forecast - By Application
    • 8.3.1. Cell Culture
    • 8.3.2. Vaccine Testing
    • 8.3.3. Virus Testing
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Biopharmaceutical & Biotechnology Companies
    • 8.4.2. Cell banks
    • 8.4.3. Contract Research Organizations & Contract Manufacturing Organizations
    • 8.4.4. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.5.1. Japan
      • 8.5.1.1. By Testing Method
    • 8.5.2. China
      • 8.5.2.1. By Testing Method
    • 8.5.3. India
      • 8.5.3.1. By Testing Method
    • 8.5.4. Australia
      • 8.5.4.1. By Testing Method
    • 8.5.5. Southeast Asia
      • 8.5.5.1. By Testing Method
    • 8.5.6. Rest of Asia Pacific
      • 8.5.6.1. By Testing Method

9. Rest of the World Mycoplasma Testing Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Testing Method
    • 9.1.1. PCR-based
    • 9.1.2. Culture-based
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Product
    • 9.2.1. Instruments
    • 9.2.2. Reagents & Kits
  • 9.3. Market Analysis, Insights and Forecast - By Application
    • 9.3.1. Cell Culture
    • 9.3.2. Vaccine Testing
    • 9.3.3. Virus Testing
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Biopharmaceutical & Biotechnology Companies
    • 9.4.2. Cell banks
    • 9.4.3. Contract Research Organizations & Contract Manufacturing Organizations
    • 9.4.4. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Merck KGaA
      • 10.2.1.1. Overview
      • 10.2.1.2. Product
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. financials (Based on Availability)
    • 10.2.2. Thermo Fisher Scientific Inc.
      • 10.2.2.1. Overview
      • 10.2.2.2. Product
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. financials (Based on Availability)
    • 10.2.3. F. Hoffmann-La Roche Ltd.
      • 10.2.3.1. Overview
      • 10.2.3.2. Product
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. financials (Based on Availability)
    • 10.2.4. Sartorius AG
      • 10.2.4.1. Overview
      • 10.2.4.2. Product
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. financials (Based on Availability)
    • 10.2.5. Asahi Kasei Corporation
      • 10.2.5.1. Overview
      • 10.2.5.2. Product
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. financials (Based on Availability)
    • 10.2.6. Biomeriux SA
      • 10.2.6.1. Overview
      • 10.2.6.2. Product
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. financials (Based on Availability)
    • 10.2.7. Charles River Laboratories
      • 10.2.7.1. Overview
      • 10.2.7.2. Product
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. financials (Based on Availability)
    • 10.2.8. ATCC
      • 10.2.8.1. Overview
      • 10.2.8.2. Product
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. financials (Based on Availability)
    • 10.2.9. Other Prominent Players

List of Tables

  • Table 1: Global Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 2: Global Mycoplasma Testing Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 3: Global Mycoplasma Testing Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 4: Global Mycoplasma Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 5: Global Mycoplasma Testing Market Revenue (USD million) Forecast, by Region, 2021-2034
  • Table 6: North America Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 7: North America Mycoplasma Testing Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 8: North America Mycoplasma Testing Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 9: North America Mycoplasma Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 10: North America Mycoplasma Testing Market Revenue (USD million) Forecast, By Country, 2021-2034
  • Table 11: U.S. Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 12: Canada Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 13: Europe Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 14: Europe Mycoplasma Testing Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 15: Europe Mycoplasma Testing Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 16: Europe Mycoplasma Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 17: Europe Mycoplasma Testing Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 18: U.K. Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 19: Germany Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 20: France Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 21: Italy Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 22: Spain Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 23: Rest of Europe Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 24: Asia Pacific Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 25: Asia Pacific Mycoplasma Testing Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 26: Asia Pacific Mycoplasma Testing Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 27: Asia Pacific Mycoplasma Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034
  • Table 28: Asia Pacific Mycoplasma Testing Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 29: China Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 30: Japan Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 31: India Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 32: Australia Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 33: Southeast Asia Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 34: Rest of Asia Pacific Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 35: Rest of the World Mycoplasma Testing Market Revenue (USD million) Forecast, by Testing Method, 2021-2034
  • Table 36: Rest of the World Mycoplasma Testing Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 37: Rest of the World Mycoplasma Testing Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 38: Rest of the World Mycoplasma Testing Market Revenue (USD million) Forecast, by End-user, 2021-2034

List of Figures

  • Figure 1: Global Mycoplasma Testing Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
  • Figure 2: Global Mycoplasma Testing Market Value Share (%), by Testing Method, 2025 & 2034
  • Figure 3: Global Mycoplasma Testing Market Value Share (%), by Product, 2025 & 2034
  • Figure 4: Global Mycoplasma Testing Market Value Share (%), by Application, 2025 & 2034
  • Figure 5: Global Mycoplasma Testing Market Value Share (%), by End-user, 2025 & 2034
  • Figure 6: Global Mycoplasma Testing Market Value (USD million), by Region, 2025 & 2034
  • Figure 7: North America Mycoplasma Testing Market Value (USD million), by Testing Method, 2025 & 2034
  • Figure 8: North America Mycoplasma Testing Market Value Share (%), by Testing Method, 2025
  • Figure 9: North America Mycoplasma Testing Market Value (USD million), by Product, 2025 & 2034
  • Figure 10: North America Mycoplasma Testing Market Value Share (%), by Product, 2025
  • Figure 11: North America Mycoplasma Testing Market Value (USD million), by Application, 2025 & 2034
  • Figure 12: North America Mycoplasma Testing Market Value Share (%), by Application, 2025
  • Figure 13: North America Mycoplasma Testing Market Value (USD million), by End-user, 2025 & 2034
  • Figure 14: North America Mycoplasma Testing Market Value Share (%), by End-user, 2025
  • Figure 15: North America Mycoplasma Testing Market Value (USD million), By Country, 2025 & 2034
  • Figure 16: North America Mycoplasma Testing Market Value Share (%), By Country, 2025
  • Figure 17: Europe Mycoplasma Testing Market Value (USD million), by Testing Method, 2025 & 2034
  • Figure 18: Europe Mycoplasma Testing Market Value Share (%), by Testing Method, 2025
  • Figure 19: Europe Mycoplasma Testing Market Value (USD million), by Product, 2025 & 2034
  • Figure 20: Europe Mycoplasma Testing Market Value Share (%), by Product, 2025
  • Figure 21: Europe Mycoplasma Testing Market Value (USD million), by Application, 2025 & 2034
  • Figure 22: Europe Mycoplasma Testing Market Value Share (%), by Application, 2025
  • Figure 23: Europe Mycoplasma Testing Market Value (USD million), by End-user, 2025 & 2034
  • Figure 24: Europe Mycoplasma Testing Market Value Share (%), by End-user, 2025
  • Figure 25: Europe Mycoplasma Testing Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Mycoplasma Testing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Mycoplasma Testing Market Value (USD million), by Testing Method, 2025 & 2034
  • Figure 28: Asia Pacific Mycoplasma Testing Market Value Share (%), by Testing Method, 2025
  • Figure 29: Asia Pacific Mycoplasma Testing Market Value (USD million), by Product, 2025 & 2034
  • Figure 30: Asia Pacific Mycoplasma Testing Market Value Share (%), by Product, 2025
  • Figure 31: Asia Pacific Mycoplasma Testing Market Value (USD million), by Application, 2025 & 2034
  • Figure 32: Asia Pacific Mycoplasma Testing Market Value Share (%), by Application, 2025
  • Figure 33: Asia Pacific Mycoplasma Testing Market Value (USD million), by End-user, 2025 & 2034
  • Figure 34: Asia Pacific Mycoplasma Testing Market Value Share (%), by End-user, 2025
  • Figure 35: Asia Pacific Mycoplasma Testing Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Mycoplasma Testing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Rest of the World Mycoplasma Testing Market Value (USD million), by Testing Method, 2025 & 2034
  • Figure 38: Rest of the World Mycoplasma Testing Market Value Share (%), by Testing Method, 2025
  • Figure 39: Rest of the World Mycoplasma Testing Market Value (USD million), by Product, 2025 & 2034
  • Figure 40: Rest of the World Mycoplasma Testing Market Value Share (%), by Product, 2025
  • Figure 41: Rest of the World Mycoplasma Testing Market Value (USD million), by Application, 2025 & 2034
  • Figure 42: Rest of the World Mycoplasma Testing Market Value Share (%), by Application, 2025
  • Figure 43: Rest of the World Mycoplasma Testing Market Value (USD million), by End-user, 2025 & 2034
  • Figure 44: Rest of the World Mycoplasma Testing Market Value Share (%), by End-user, 2025
  • Figure 45: Global Mycoplasma Testing Market Share (%), By Company, 2025